A kratom beverage maker says its products remain lawful amid a recent FDA crackdown, arguing regulators are targeting synthetic 7-hydroxymitragynine (7-OH) rather than preparations made from natural kratom leaf. Company leadership maintains any 7-OH present forms only in trace amounts during traditional drying, distinguishing it from concentrated, lab-made versions drawing scrutiny. The FDA has warned 7-OH can bind to opioid receptors and may be more potent than morphine, noting rising availability of kratom items in convenience and vape stores. Kratom is used anecdotally for relief ranging from anxiety to opioid withdrawal, but no kratom-based medicines are FDA approved, and health experts continue to flag safety and dosing risks. Read the original report at Scripps News.
Company Says Natural Kratom Products Are Outside FDA’s Focus
